BRCA1 and BRCA2 families and the risk of skin cancer

BRCA1 and BRCA2 mutation carriers have elevated risks of breast and ovarian cancers. The risks for cancers at other sites remain unclear. Melanoma has been associated with BRCA2 mutations in some studies, however, few surveys have included non-melanoma skin cancer. We followed 2729 women with a BRCA...

Full description

Saved in:
Bibliographic Details
Published in:Familial cancer 2010-12, Vol.9 (4), p.489-493
Main Authors: Ginsburg, Ophira M., Kim-Sing, Charmaine, Foulkes, William D., Ghadirian, Parviz, Lynch, Henry T., Sun, Ping, Narod, Steven A.
Format: Article
Language:English
Subjects:
Biomedical and Life Sciences
Biomedicine
BRCA1 Protein - genetics
BRCA2 Protein - genetics
Cancer Research
Carcinoma, Basal Cell - genetics
Carcinoma, Basal Cell - pathology
Epidemiology
Female
Follow-Up Studies
Genetic Predisposition to Disease
Genetic Testing
Heterozygote
Human Genetics
Humans
Male
Melanoma - genetics
Melanoma - pathology
Mutation - genetics
Pedigree
Risk Factors
Skin Neoplasms - genetics
Skin Neoplasms - pathology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:BRCA1 and BRCA2 mutation carriers have elevated risks of breast and ovarian cancers. The risks for cancers at other sites remain unclear. Melanoma has been associated with BRCA2 mutations in some studies, however, few surveys have included non-melanoma skin cancer. We followed 2729 women with a BRCA1 or BRCA2 mutation for an average of 5.0 years. These women were asked to report new cases of cancer diagnosed in themselves or in their family. The risks of skin cancer were compared for probands with BRCA1 and BRCA2 mutations. Of 1779 women with a BRCA1 mutation, 29 developed skin cancer in the follow-up period (1.6%). Of the 950 women with a BRCA2 mutation, 28 developed skin cancer (3.0%) (OR = 1.83 for BRCA2 versus BRCA1; 95% CI 1.08–3.10; P  = 0.02). The odds ratio for basal cell carcinoma was higher (OR = 3.8; 95% CI 1.5–9.4; P  = 0.002). BRCA2 mutation carriers are at increased risk for skin cancer, compared with BRCA1 carriers, in particular for basal cell carcinoma.
ISSN:1389-9600
1573-7292
DOI:10.1007/s10689-010-9377-y